As an endocrinologist, I work with patients every day who struggle with metabolic syndrome, a combination of conditions like abdominal obesity, elevated blood sugar, high triglycerides, low HDL cholesterol, and hypertension. Despite the use of medications targeting insulin resistance, dyslipidemia, and hypertension, many patients continue to progress towards diabetes and cardiovascular disease.
New research shows that the gut microbiome may be key to managing or reversing metabolic syndrome. The gut microbiome functions as an endocrine organ, producing metabolites that influence glucose homeostasis, lipid metabolism, and energy regulation.
What happens in the altered gut microbiome is that it affects the incretin production, particularly GLP-1 and GIP, hormones central to glucose regulation and satiety. Many of my patients with poor incretin responses show significant microbiome alterations.
Additionally, the gut microbiome influences circadian rhythm regulation of metabolic hormones. I have observed that patients with metabolic syndrome and microbiome disturbances often exhibit abnormal cortisol curves and melatonin production, further compromising their metabolic health.
This leads to unconventional therapy called the Faecal Microbiota Transplantation.
This FMT involves transferring processed stool from a healthy donor into a patient’s gastrointestinal tract, essentially repopulating their gut with a more diverse and balanced community of microbes.
Why is this needed? Because the gut microbiota influences systemic inflammation, insulin sensitivity, and energy metabolism. All of which are dysregulated in the metabolic syndrome. People with metabolic syndrome often show a less diverse microbiome with fewer beneficial bacteria and more pro-inflammatory species. By restoring microbial balance, we hope to improve metabolic pathways that are otherwise dysfunctional.
FMT appears to reduce circulating levels of branched-chain amino acids and aromatic amino acids, which are typically elevated in insulin-resistant states and may contribute to pancreatic beta-cell dysfunction.
Clinical trials of 9 studies show that FMT led to modest short-term improvements in fasting blood glucose, HbA1c, insulin levels, and HDL cholesterol. However, similar to previous findings, there were no significant effects on weight reduction, highlighting the limited impact of FMT on obesity-related measures.
It is important to note that FMT for metabolic syndrome is still in the early experimental phase. It’s not FDA-approved for this indication, and more robust data is needed to understand who it might help, and for how long.
As we move toward more personalised medicine, microbiome-targeted therapies, whether through FMT, probiotics, or dietary modulation, could become powerful tools in our fight against metabolic disease. Until then, we focus on nutritional therapy, physical activity, weight management, and medication when needed.
Kripa, is a Specialist Dietitian at The London Obesity & Endocrine Clinic. She has helped many patients overcome weight management barriers. ©Simplyweight
Top obesity clinic in Chennai
